MarketPulse

BTK inhibitor

2 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Hutchmed (China) Limited

HUTCHMED Advances Cancer Pipeline with Phase III HMPL-760 Trial Launch

HUTCHMED initiates Phase III trial of HMPL-760 for relapsed/refractory lymphoma in China, enrolling 240 patients following positive Phase II results.
HCMclinical developmentoncology
The Motley FoolThe Motley Fool··Motley Fool Transcribing

Curis Posts Surprise Profit on Erivedge Sale, Pivots to Lymphoma Pipeline

$CRIS reports $19.4M Q4 earnings from one-time Erivedge sale; refocuses on PCNSL and CLL studies with $20.2M PIPE funding.
CRISearningsclinical trials